HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Holroyd-Leduc, J. M Search for Related Content PubMed Articles by Holroyd-Leduc, J. M

Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease

Clinical impact ratings GP/FP/Primary care IM/Ambulatory care Neurology Geriatrics

Key Words: Alzheimer’s disease • cholinesterase inhibitors

The first 150 words of the full text of this article appear below.

METHODS
Design: randomised controlled trial (AD2000 study).

Allocation: {concealed^*}.

Blinding: blinded {patients, healthcare providers, data collectors, and outcome assessors}.^*

Follow up period: 3 years.

Setting: 22 hospitals in the UK.

Patients: 566 patients (59% women, median age 75–76 y) who were referred to memory clinics with a suspected DSM-IV diagnosis of dementia of Alzheimer type, with or without coexisting vascular dementia; had a regular carer; lived in the community; were not taking a cholinesterase inhibitor; and had no contraindications to donepezil.

Intervention: during a 12 week run in period, patients were allocated to donepezil, 5 mg/day (n = 283), or placebo (n = 283). 511 patients completed this run in period, and 486 were re-randomised to donepezil, 5 or 10 mg/day (n = 242), or placebo (n = 244) for 48 weeks. After a 6 week no-treatment washout, patients could continue with the same treatment for another 48 . . . [Full text of this article]

Jayna M Holroyd-Leduc, MD, FRCPC

University of Toronto
Toronto, Ontario, Canada